NEW DELHI :
India will export hydroxychloroquine, an antimalarial drug that is in high demand around the world, only to foreign governments and not to private companies because the product is in a prohibited or prohibited export category, officials said. sources.
Although exports of this drug are completely prohibited, India has decided to export this antimalarial drug in synchronization with its global commitment to fight the coronavirus pandemic.
“Hydroxychloroquine continues to be a banned product. A private-to-private business or a domestic exporter to a foreign importer is prohibited. The procedure the government adopts is to help the countries that need it the most or are traditionally dependent India for this drug or friendly countries like Nepal, Sri Lanka and Bhutan, “said the sources.
Explaining the procedure, they said that countries that need to import hydroxychloroquine should send their requests through the Department of External Affairs.
The Pharmaceuticals Department would assess the requirement sought by this country and would see its impact on the availability of India and without compromising the interests of India, it would recommend to the General Directorate of Foreign Trade (DGFT) to give a license or give the green light to the customs authorities. to release the shipment.
The DGFT is a branch of the Ministry of Commerce which deals with export and import issues. It is the agency that grants the license or authorization or the certificate of no objection for exports or imports.
On March 25, India banned the export of hydroxychloroquine, with a few exceptions, while some believed that the drug could be used to fight COVID-19. On April 4, he completely prohibited exports without exception.
In a telephone conversation with Prime Minister Narendra Modi last week, President Donald Trump sought to supply hydroxychloroquine to the United States.
Hydroxychloroquine is an old, inexpensive drug used to treat malaria. India is the largest producer and exporter of the drug in the world.
It is reported that India has received requests from more than 20 countries, including its immediate neighbors, Sri Lanka and Nepal, for supplies.
The Indian pharmaceutical industry has stated that there is sufficient stock of hydroxychloroquine in the country, and the pharmaceutical companies are ready to increase production to meet domestic and export needs.
India produces 70% of the world supply of hydroxychloroquine. Companies like Zydus Cadila and IPCA are the country’s leading manufacturers, according to the Indian Pharmaceutical Alliance (IPA).
Rakesh Mohan Joshi, a professor at the Indian Institute for Foreign Trade (IIFT), said India is the world’s largest manufacturer and supplier, accounting for around 70% of global supplies.
In the U.S. market, India accounted for about 47% of the supply of hydroxychloroquine in 2019, he said.
Ashok Kumar Madan, Executive Director of the Indian Association of Indian Drug Manufacturers (IDMA), said that India currently has an annual installed capacity of around 40 tonnes of active pharmaceutical ingredients (API) of hydroxychloroquine. With this capacity, “we can make approximately 200 million 200 mg tablets,” he said.
India exported API of hydroxychloroquine for USD 1.22 billion in April-January 2019-20. Over the same period, exports of hydroxycholoroquine formulations totaled $ 5.50 billion.
This story was published from a news agency thread without text modification. Only the title has been changed.